Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7

Verify with FDA CVM →

24 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
2
Deaths Reported
830.0%
Death Rate

Active Ingredients

Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7

Administration Routes

Intramuscular

Species Affected

Horse 24

Most Affected Breeds

Quarter Horse 7
Warmblood (unspecified) 4
Pony of the Americas 2
Morgan 2
Tennessee Walking Horse 2
Appaloosa 1
Horse (unknown) 1
Missouri Fox Trotting Horse 1
Arab 1
Hanovarian 1

Most Reported Reactions

Fever 8
Lack of efficacy - NOS 5
Colic 5
Other abnormal test result NOS 4
Lethargy (see also Central nervous system depression in Neurological) 4
Decreased appetite 3
Injection site swelling 3
Swollen limb 3
Weight loss 3
Facial swelling (see also 'Skin') 2
Injection site inflammation 2
Ataxia 2

Outcome Breakdown

Recovered/Normal
11 (45.8%)
Ongoing
8 (33.3%)
Outcome Unknown
3 (12.5%)
Died
1 (4.2%)
Euthanized
1 (4.2%)

Data Summary

Metric Value
Total adverse event reports 24
Reports involving death 2
Case-fatality rate (reported events) 830.0%
Distinct species in reports 1
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 24 adverse event reports referencing Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7, including 2 reports in which the animal died — a 830.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7. Reported administration route is Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7 reports are Horse (24 reports), with Horse accounting for the largest share. Within those species, Quarter Horse (7), Warmblood (unspecified) (4), Pony of the Americas (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7 are Fever (8), Lack of efficacy - NOS (5), Colic (5), Other abnormal test result NOS (4). Of the 24 reports with a coded outcome, Recovered/Normal is the leading category at 45.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Equine Herpes Virus Strain 405/76, H.D. 3-15-91;Equine Herpes Virus Strain 438/7.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial